Afatinib (BIBW2992)

Catalog No.S1011

Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Afatinib (BIBW2992) Chemical Structure

Afatinib (BIBW2992) Chemical Structure
Molecular Weight: 485.94

Validation & Quality Control

Cited by 35 publications:

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Selective EGFR Inhibitor

    Erlotinib HCl (OSI-744) EGFR-selective, IC50=2 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

  • Classic EGFR Inhibitor

    WZ4002 Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Inhibition Profile
  • Afatinib (BIBW2992) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Targets EGFR (L858R) [1]
(Cell-free assay)
EGFR (wt) [1]
(Cell-free assay)
EGFR (L858R/T790M) [1]
(Cell-free assay)
HER2 [1]
(Cell-free assay)
IC50 0.4 nM 0.5 nM 10 nM 14 nM
In vitro BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HDLM-2NWT1ZpBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TacWlEPTB;MD6wNFU4OiEQvF2=NIr2[5VUSU6JRWK=
KASUMI-1NEHZWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jtfmlEPTB;MD6wNFkyOSEQvF2=M2XnUXNCVkeHUh?=
HCC2218M4[0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XBZWlEPTB;MD6wNFk5PyEQvF2=M2XLfHNCVkeHUh?=
KARPAS-45NXP5fHY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHxbodKSzVyPUCuNFE3PzFizszNMmjSV2FPT0WU
HSC-4MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7CTWM2OD1yLkCxO|Q5KM7:TR?=NYHPNmFiW0GQR1XS
CHL-1M1:5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkD2TWM2OD1yLkCxPFM6KM7:TR?=NYD0O2JSW0GQR1XS
KY821MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjQUGtpUUN3ME2wMlAzODZizszNNHX4NmZUSU6JRWK=
NCI-N87M{ewXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTBwMEK3O|Mh|ryPMUTTRW5ITVJ?
DOKM2XEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfFN3FKSzVyPUCuNFMyQTRizszNMlPiV2FPT0WU
DSH1NHq3Z3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTBwMEOzNVQh|ryPNF;SZopUSU6JRWK=
MDA-MB-175-VIINULDeY9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFThOGxKSzVyPUCuNFM1OTZizszNNXj2XJU{W0GQR1XS
NCI-H2170M125bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3jc2tKSzVyPUCuNFM4OjhizszNM1LzNHNCVkeHUh?=
BT-474MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjlV41KSzVyPUCuNFQ6QDZizszNMVvTRW5ITVJ?
EFO-27NGfYVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXMO4xKSzVyPUCuNFUyQDJizszNNIPtUXNUSU6JRWK=
NCI-H720M1ywc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXtPYYyUUN3ME2wMlA2OzJ3IN88US=>NYrlcnVsW0GQR1XS
PC-14NIXTd2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\UVllVUUN3ME2wMlA2PjZ6IN88US=>MYfTRW5ITVJ?
EC-GI-10M4SwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4D3OGlEPTB;MD6wOVkyOiEQvF2=M{DNUHNCVkeHUh?=
KYSE-450MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXGTWM2OD1yLkC1PVc5KM7:TR?=NVLx[HFHW0GQR1XS
BPH-1NF70d2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M131b2lEPTB;MD6wOVk5QCEQvF2=NXzZSXVCW0GQR1XS
NCI-H292NFjrOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1n1U2lEPTB;MD6wOlA6KM7:TR?=MnjnV2FPT0WU
H9Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLLcYlKSzVyPUCuNFcyOzJizszNMVXTRW5ITVJ?
NCI-H526NYHycJB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTBwMEe4NlMh|ryPMW\TRW5ITVJ?
NCI-H1623Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrUTFNiUUN3ME2wMlA5ODJ3IN88US=>MmXDV2FPT0WU
KYSE-140MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETvTpdKSzVyPUCuNFg{OyEQvF2=NIW0U|NUSU6JRWK=
Ca9-22MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTBwMEizOVMh|ryPM3[zc3NCVkeHUh?=
AU565MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrsOmJMUUN3ME2wMlA5PTB2IN88US=>NWrCTIRTW0GQR1XS
ZR-75-30M4roeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorXTWM2OD1yLkC5OVQ2KM7:TR?=M4DrPHNCVkeHUh?=
NCI-H1770Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITiZoNKSzVyPUCuNVAzQCEQvF2=MnT5V2FPT0WU
LB2241-RCCNHrVcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXVWppKSzVyPUCuNVA5QDRizszNM{e2ZXNCVkeHUh?=
CAL-39NHrUeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTBwMUG3PVIh|ryPM{Ly[3NCVkeHUh?=
UACC-893NHjsZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFP5OZdKSzVyPUCuNVE5QDVizszNMmXkV2FPT0WU
LU-65M4TJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zuUGlEPTB;MD6xNlY{OyEQvF2=NYTpS44yW0GQR1XS
HNM13TSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLLTWM2OD1yLkGzNFc4KM7:TR?=M17tVHNCVkeHUh?=
TI-73MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTBwMUS3NVUh|ryPMnjVV2FPT0WU
KU812M{jXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTBwMUW0OVYh|ryPNXHkOXBiW0GQR1XS
SW13MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nweWlEPTB;MD6xOlIyPiEQvF2=NH3IXYdUSU6JRWK=
BB30-HNCNWPXU3RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTBwMU[1O|Yh|ryPMUfTRW5ITVJ?
HSC-2NIjBelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTBwMU[4N|ch|ryPNI\XSHNUSU6JRWK=
BV-173M{jidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDD[WpFUUN3ME2wMlE4PTl4IN88US=>MXPTRW5ITVJ?
CAL-27MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\HTWM2OD1yLkG3OlM3KM7:TR?=NWr0PI5vW0GQR1XS
SBC-1NGWwZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLtTWM2OD1yLkG4PVU6KM7:TR?=NHzmVo9USU6JRWK=
CAL-33MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHPTJM6UUN3ME2wMlIxOTh2IN88US=>MVvTRW5ITVJ?
NCI-H209MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rLPGlEPTB;MD6yNFQ3KM7:TR?=MVrTRW5ITVJ?
COR-L105NHjYTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTBwMkGwPFQh|ryPNFHWSmxUSU6JRWK=
HSC-3M1nnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoH6TWM2OD1yLkKxNVk5KM7:TR?=NXHoU456W0GQR1XS
NCI-H69MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLXVFFKSzVyPUCuNlE1PTFizszNNYn3R|hMW0GQR1XS
MOLT-13NH;YVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTBwMkO5O|Uh|ryPMojwV2FPT0WU
ML-2NXftWYpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTBwMkS4NFIh|ryPMl3PV2FPT0WU
IGROV-1MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjER|l3UUN3ME2wMlI2QTV{IN88US=>MXjTRW5ITVJ?
TK10NIXyNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTBwMk[3N|gh|ryPNYrpfXpZW0GQR1XS
EoL-1-cellNWXG[2FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfkOopZUUN3ME2wMlI3QDl{IN88US=>MWXTRW5ITVJ?
HO-1-N-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTBwMke4OVMh|ryPNEXtTGFUSU6JRWK=
BHYNGXGZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;WXmlEPTB;MD6yPFY2PSEQvF2=NG\2c5RUSU6JRWK=
LU-139MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojNTWM2OD1yLkOwOVEh|ryPNE\COoxUSU6JRWK=
23132-87MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXXTWM2OD1yLkOxPVI{KM7:TR?=M4X5N3NCVkeHUh?=
ACHNMn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHxcmxKSzVyPUCuN|E6QTRizszNNXTO[lZrW0GQR1XS
DoTc2-4510NYnsbpV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTBwM{KyNVkh|ryPNFfMb3FUSU6JRWK=
BB65-RCCM1;BVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\DVpE4UUN3ME2wMlM1PTl|IN88US=>M3P5WXNCVkeHUh?=
HLEM3T4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7UZmluUUN3ME2wMlM2ODR4IN88US=>MonHV2FPT0WU
HCC1419MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLaXo96UUN3ME2wMlM3PDB6IN88US=>MXHTRW5ITVJ?
A388NIDhVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlS3TWM2OD1yLkO2PFU4KM7:TR?=NXjETmN{W0GQR1XS
NUGC-3NYTGe3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mli1TWM2OD1yLkO4N|c{KM7:TR?=M3X3TXNCVkeHUh?=
KYSE-180M4X0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XDd2lEPTB;MD6zPVA5QSEQvF2=NHfTSpJUSU6JRWK=
TE-6MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnqTWM2OD1yLkSwNlQ3KM7:TR?=MmHJV2FPT0WU
A498MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjO[VBKSzVyPUCuOFA3PzRizszNM1[wOnNCVkeHUh?=
NCI-H1648NXHGZpB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHwfoVKSzVyPUCuOFQyQDJizszNM{\BVHNCVkeHUh?=
DU-145MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTBwNES4N|Mh|ryPMlnOV2FPT0WU
CW-2MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXiNZNyUUN3ME2wMlQ3QTF2IN88US=>MUjTRW5ITVJ?
A431NIWyWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnWwTWM2OD1yLkS4NlM{KM7:TR?=MontV2FPT0WU
SASNHjac3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHUTWM2OD1yLkS4N|k5KM7:TR?=MnnLV2FPT0WU
NCI-H2126MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fZfWlEPTB;MD61NVkzPiEQvF2=MWfTRW5ITVJ?
NCI-H358NYTPPWt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzRS49PUUN3ME2wMlU{OjFizszNMmG3V2FPT0WU
FADUNVe3OIdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHzdZhKSzVyPUCuOVQ1ODRizszNNIToPIpUSU6JRWK=
ACNNIjRbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTBwNUWwPVQh|ryPMXHTRW5ITVJ?
HCC70NHq0fFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLlTWM2OD1yLkW3OlYyKM7:TR?=NGPIU|hUSU6JRWK=
NCI-H1838M2DiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M36zbmlEPTB;MD62NFI6QSEQvF2=MWjTRW5ITVJ?
CAL-54NH7hOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\DfmN1UUN3ME2wMlYyPjJzIN88US=>MUTTRW5ITVJ?
NCI-H1975Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLITWM2OD1yLk[xO|I5KM7:TR?=NXnpPWdKW0GQR1XS
COR-L88NEHPRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rzNGlEPTB;MD62OFEyOyEQvF2=Ml;TV2FPT0WU
CTV-1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYizWFRFUUN3ME2wMlY1Ozl{IN88US=>MnnCV2FPT0WU
EW-18MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\lTWM2OD1yLk[4Olk5KM7:TR?=M2nEdXNCVkeHUh?=
HCC1806NXnJbIxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NISyN|ZKSzVyPUCuOlk3PjZizszNM4GyNHNCVkeHUh?=
HuP-T4MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH36SVZKSzVyPUCuOlk4PiEQvF2=NGLzWlhUSU6JRWK=
MDA-MB-361NGDRe5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTBwN{K2OlIh|ryPMoPDV2FPT0WU
NCI-H1573MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnBeFZKSzVyPUCuO|M3OyEQvF2=NXf1NG4{W0GQR1XS
KU-19-19NIn0TIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTBwN{e0OlQh|ryPMVnTRW5ITVJ?
COLO-678Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXGVmM5UUN3ME2wMlgxQDN2IN88US=>MXPTRW5ITVJ?
C-33-ANEjhTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7XTWM2OD1yLkixNlk4KM7:TR?=NVzZSW51W0GQR1XS
Calu-3NHjYbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPmSIpQUUN3ME2wMlgyPDN2IN88US=>M3WyVnNCVkeHUh?=
AGSNEjRfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLVTWM2OD1yLkizOlQ5KM7:TR?=MUnTRW5ITVJ?
SCC-25MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnkTWM2OD1yLki0NVcyKM7:TR?=MWDTRW5ITVJ?
JVM-2NYryc5luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjsN3ZRUUN3ME2wMlg5Ojl7IN88US=>NYLp[GtvW0GQR1XS
HCE-TMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\uTWM2OD1yLki4OFI5KM7:TR?=M36yb3NCVkeHUh?=
ES4NFLGNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTBwOUe4N|Yh|ryPNXXteIdHW0GQR1XS
EKVXMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3RTnRpUUN3ME2xMlAyODZ2IN88US=>MW\TRW5ITVJ?
D-542MGM1HufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXmxUIZ2UUN3ME2xMlAyODZ2IN88US=>M4n4dnNCVkeHUh?=
SW1116Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjGbVZKSzVyPUGuNFEzQDdizszNNETKUWZUSU6JRWK=
5637MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XQNGlEPTB;MT6wNVUyKM7:TR?=MnP5V2FPT0WU
HT-1376NHq1WWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jo[2lEPTB;MT6wNVUyOyEQvF2=Ml\QV2FPT0WU
NB69NFzacGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTFwMEK5OFUh|ryPMWnTRW5ITVJ?
YKG-1NHvrS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYqzSIU6UUN3ME2xMlA2PDF7IN88US=>M2HCRXNCVkeHUh?=
EW-3NInSXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoriTWM2OD1zLkC3PFg{KM7:TR?=NUjS[nE4W0GQR1XS
GCIYM3qwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTFwMEixNFQh|ryPMlLIV2FPT0WU
SK-MES-1MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDvRohrUUN3ME2xMlEyPDh5IN88US=>MmftV2FPT0WU
PANC-08-13M2\MdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPLTWM2OD1zLkG2OFE3KM7:TR?=MmmwV2FPT0WU
SK-NEP-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTFwMUe1NVMh|ryPNF7yTYRUSU6JRWK=
SW954M3fPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTFwMkCyNVQh|ryPNWPWR2Q6W0GQR1XS
NCI-SNU-5MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\SdWNKSzVyPUGuNlM6KM7:TR?=Mn\YV2FPT0WU
SW48NIjRS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTFwMkW0N|Ih|ryPNHKy[ZhUSU6JRWK=
HT-3MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NICzdpNKSzVyPUGuNlg4PTNizszNMX3TRW5ITVJ?
ETK-1MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTKTWM2OD1zLkO3OFU3KM7:TR?=NIjiWYxUSU6JRWK=
SCC-15M3y4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTsfGZKSzVyPUGuN|k1PTFizszNNX\P[Xp3W0GQR1XS
DU-4475NYLycHR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LlbmlEPTB;MT60NFEzOSEQvF2=NWn0XVI3W0GQR1XS
NB5Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTFwNEGzNVch|ryPNF\pZYVUSU6JRWK=
CFPAC-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknUTWM2OD1zLkSyOFk{KM7:TR?=M13PWnNCVkeHUh?=
NCI-H630NWqxWI1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnhZ|FKSzVyPUGuOFU2QDJizszNNIi1NItUSU6JRWK=
NCI-H82NIPT[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LFbmlEPTB;MT61OFAxPiEQvF2=M{fNNHNCVkeHUh?=
ECC10MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4W4VGlEPTB;MT61OVM3QSEQvF2=M37pOXNCVkeHUh?=
K5MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDveIpKSzVyPUGuOVg{PTdizszNMXrTRW5ITVJ?
ME-180NEGw[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fuUmlEPTB;MT62NVA6PiEQvF2=MWjTRW5ITVJ?
KYSE-410M3fONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHtOGd7UUN3ME2xMlY2Pjd{IN88US=>NHzCTlFUSU6JRWK=
G-401NF:2R5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoewTWM2OD1zLk[3OFE{KM7:TR?=MUHTRW5ITVJ?
TGBC24TKBNVXFZY8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zXUmlEPTB;MT62PFI{KM7:TR?=Mn3BV2FPT0WU
Detroit562M4jzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvqZldKSzVyPUGuO|AyPTJizszNMYrTRW5ITVJ?
OE19M33FXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHi1V4xKSzVyPUGuO|E2OTJizszNNXvTTo5rW0GQR1XS
CAKI-1M2nqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzjUmhKSzVyPUGuO|gzOTFizszNNV3aeVU6W0GQR1XS
TE-12NG\Hc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTFwOEC0NVQh|ryPM{\Yb3NCVkeHUh?=
NCI-H1666NIDO[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoG4TWM2OD1zLkiwPVQ5KM7:TR?=MUTTRW5ITVJ?
TE-1NETlTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzQPWw5UUN3ME2xMlgyPDd3IN88US=>M3TMRnNCVkeHUh?=
CAL-12TM1nH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITQTGlKSzVyPUGuPFg6PDVizszNM{e2[3NCVkeHUh?=
TE-8M1jNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zWN2lEPTB;MT65NVM4PyEQvF2=NVrCV5A2W0GQR1XS
KYSE-270NV;IboZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zFXWlEPTB;Mj6wNlc{OiEQvF2=NHfUZ2JUSU6JRWK=
GMS-10M37X[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfTTWM2OD1{LkCzOVE4KM7:TR?=MlLSV2FPT0WU
A2780MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTJwME[yPVQh|ryPNFPPc49USU6JRWK=
OMC-1NH3IZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkm1TWM2OD1{LkC4NVY6KM7:TR?=Mo[0V2FPT0WU
LoVoNGDOb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY[wd2ZCUUN3ME2yMlExPzl5IN88US=>M{O5c3NCVkeHUh?=
PANC-03-27NGXoZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\YTWM2OD1{LkG2OlMyKM7:TR?=NWizS3o2W0GQR1XS
MDA-MB-157MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\G[W5GUUN3ME2yMlIyQDJ6IN88US=>MoX5V2FPT0WU
CaR-1NWnmXJVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjDTWM2OD1{LkK4NlgyKM7:TR?=M3zZSXNCVkeHUh?=
769-PMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXwTWM2OD1{LkK5NFM4KM7:TR?=MX;TRW5ITVJ?
NB7NUTzNHVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUj6XVMxUUN3ME2yMlI6Pjd4IN88US=>MWnTRW5ITVJ?
MKN7MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoK1TWM2OD1{LkO1N|M2KM7:TR?=NUnPb|ZiW0GQR1XS
NCI-H1048MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWP3[21JUUN3ME2yMlQ6OTV6IN88US=>MW\TRW5ITVJ?
RCM-1NWLyXmoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\sOIVKSzVyPUKuOVI6OzhizszNNUnBZ5ZiW0GQR1XS
HT55MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7NTWM2OD1{LkW3N|gh|ryPMk[4V2FPT0WU
HCC1569MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTJwNUiyPVch|ryPM3LMUnNCVkeHUh?=
LXF-289M2ThZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXzXm1yUUN3ME2yMlY{PTZ3IN88US=>MUPTRW5ITVJ?
OVCAR-3NFnUcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfYO29KSzVyPUKuOlcyPjdizszNNXLqWlZuW0GQR1XS
TE-10M4nKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHYTWM2OD1{Lk[4NFc5KM7:TR?=NXrjOJg3W0GQR1XS
SNU-C2BM1zSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LqZWlEPTB;Mj62PFYyPiEQvF2=NF3LSIRUSU6JRWK=
LB1047-RCCMo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTJwN{S4PFgh|ryPM1z0ZXNCVkeHUh?=
SN12CNWDqOG1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\1XWNKSzVyPUKuPVE6PjRizszNNUnQWFZCW0GQR1XS
786-0MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PMW2lEPTB;Mz6wOlQxQCEQvF2=NV;EWmZ7W0GQR1XS
HT-29NVeyTo9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfnOFVKSzVyPUOuNFc{ODlizszNM3HzdHNCVkeHUh?=
RPMI-7951M3vNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTNwMEe1PUDPxE1?NHPBXIxUSU6JRWK=
NBsusSRNEX3XpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XNd2lEPTB;Mz6xPFI2PCEQvF2=NGOxN3RUSU6JRWK=
NKM-1M4HTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvNZ4dUUUN3ME2zMlE5PzR2IN88US=>MknGV2FPT0WU
Capan-2NI\vSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rZUmlEPTB;Mz60Olg4PSEQvF2=MkfKV2FPT0WU
MKN1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3iT45CUUN3ME2zMlQ4OTB6IN88US=>NID4b2ZUSU6JRWK=
OAW-42MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTNwNUCwNlYh|ryPNGfqZVZUSU6JRWK=
SKG-IIIaNVnNbFFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDSV2JvUUN3ME2zMlUzOjN5IN88US=>MnrCV2FPT0WU
no-11NWPJV4dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\LZ41KSzVyPUOuOVM2PjRizszNNFPuPIxUSU6JRWK=
NYMoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTNwNUO2OVUh|ryPNHTqdolUSU6JRWK=
HEC-1M2[0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TG[2lEPTB;Mz61PFk2KM7:TR?=NWjkNVR4W0GQR1XS
NCI-H441M4C1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITRXYRKSzVyPUOuOVk5PDFizszNNWjOPZRoW0GQR1XS
NCI-H2009MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvae|E2UUN3ME2zMlYyOjF4IN88US=>NETpdXpUSU6JRWK=
T47DMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkHyTWM2OD1|Lk[yNlE4KM7:TR?=M2j0[XNCVkeHUh?=
SNU-449NH7XUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\JNHpKSzVyPUOuOlU5OjZizszNM2TWS3NCVkeHUh?=
NCI-SNU-1M{nQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTNwNkm3N|Uh|ryPMoTwV2FPT0WU
BT-20MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nPb2lEPTB;Mz62PVc6PSEQvF2=NXzGPGI5W0GQR1XS
LS-123MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPk[mhKSzVyPUOuO|QzQDRizszNNW[5d3RnW0GQR1XS
8305CNWL2WJFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\nVWlEPTB;Mz63OVkyOSEQvF2=NFrmbVRUSU6JRWK=
OCUB-MMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HOSGlEPTB;Mz63OlE5PyEQvF2=MoTrV2FPT0WU
KOSC-2NYXSU3RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTNwOEO0OVEh|ryPMonDV2FPT0WU
NCI-H1693NW\uXlFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTNwOESxPFEh|ryPMo\jV2FPT0WU
TE-9MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGiy[JpKSzVyPUOuPFQ{QDJizszNM4LENHNCVkeHUh?=
MV-4-11NWP2cJRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvXTpp5UUN3ME2zMlg4QTl2IN88US=>NFTuUFZUSU6JRWK=
GAMGMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;DfWlEPTB;Mz65NVMyPCEQvF2=M1rRW3NCVkeHUh?=
KNS-62NUOxdplMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfucG9zUUN3ME2zMlk1PzNzIN88US=>NVnDSpczW0GQR1XS
MC116Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTNwOUW0PFkh|ryPNEfJeGpUSU6JRWK=
647-VNYK5dGQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LT[2lEPTB;Mz65PFQ2OiEQvF2=NGLNe3RUSU6JRWK=
U-87-MGNFjjXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fYeWlEPTB;ND6xNFQ5OSEQvF2=NWDxTXZSW0GQR1XS
RPMI-8226Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvpeIR2UUN3ME20MlEyPjNzIN88US=>MkS5V2FPT0WU
SW1417Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XHVGlEPTB;ND6xNlE1PyEQvF2=NUD3[Jl2W0GQR1XS
LAMA-84MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTRwMUewNkDPxE1?MlT4V2FPT0WU
LS-513MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfFb|FKSzVyPUSuN|EzOTdizszNMVHTRW5ITVJ?
KLENIXUbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\ZU5NKSzVyPUSuOFA5OTlizszNMWPTRW5ITVJ?
HCT-116NGe2d3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLxdI5YUUN3ME20MlQyODB5IN88US=>NWPscZpOW0GQR1XS
EPLC-272HNY\NN4t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTC[VRMUUN3ME20MlQyPTN|IN88US=>NHzSRndUSU6JRWK=
KS-1NVztdIhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTjOVdCUUN3ME20MlUxQDh7IN88US=>NYjMS29RW0GQR1XS
HT-1197NFPoNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTRwNUK2Olkh|ryPNFPNNHhUSU6JRWK=
LCLC-97TM1MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTRwNUO2PFYh|ryPNX;HSJFGW0GQR1XS
ES5MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LxWWlEPTB;ND64N|czOyEQvF2=M1PIUnNCVkeHUh?=
CTB-1MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLlV49iUUN3ME20Mlg1QDhizszNM2\wTnNCVkeHUh?=
HL-60MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXr5TXNmUUN3ME20Mlg3PjFzIN88US=>MoLSV2FPT0WU
VM-CUB-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXZdJpKSzVyPUSuPFY5OTlizszNMWPTRW5ITVJ?
MEG-01NYnLc4t{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHni[pJKSzVyPUSuPVk1ODNizszNMljWV2FPT0WU
KYSE-520NILNTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrVTWM2OD13LkKwPFM6KM7:TR?=MkK1V2FPT0WU
HuO-3N1MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7QTWM2OD13LkK0NFQ{KM7:TR?=MmHhV2FPT0WU
SW620NIjLbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIKyTWFKSzVyPUWuNlQ6PjRizszNMknNV2FPT0WU
U031M3zafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3OSFkyUUN3ME21MlI2PDJ2IN88US=>NHXPVZNUSU6JRWK=
TE-5M3vq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUftXm56UUN3ME21MlQxQDVizszNNG\CT4RUSU6JRWK=
NCI-H747NXHtWGZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTVwNEK0O|Ih|ryPNFzCN4dUSU6JRWK=
MG-63M2\iVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofJTWM2OD13LkS4O|YzKM7:TR?=NXfwblk4W0GQR1XS
HC-1M4K2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTVwNUG4N|kh|ryPMl7HV2FPT0WU
HCC2998M4jPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTVwNUK2NVUh|ryPNXjLS|drW0GQR1XS
NTERA-S-cl-D1M4POeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\3O2lEPTB;NT61OFU{PyEQvF2=NX\aPY9OW0GQR1XS
KINGS-1Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rGN2lEPTB;NT62NFk1PCEQvF2=NHP3dmtUSU6JRWK=
D-423MGM2HPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVe2NJdCUUN3ME21MlYyPzB3IN88US=>M2OzW3NCVkeHUh?=
SW962NVPX[nlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTVwNkKwN|Ih|ryPNET0[|lUSU6JRWK=
LOXIMVIMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTVwNkO4O|Mh|ryPM2PiTnNCVkeHUh?=
LS-411NMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHkTWM2OD13Lke5OFQyKM7:TR?=MUjTRW5ITVJ?
NCI-H2291MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvoTWM2OD13Lkm4PVQ{KM7:TR?=NGj6emxUSU6JRWK=
A549MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUW5U5h2UUN3ME22MlEzPTV|IN88US=>Mn;TV2FPT0WU
LS-1034NVWxTo1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rBbWlEPTB;Nj6yNFcxPiEQvF2=NW\hS2pIW0GQR1XS
NB14MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInHfllKSzVyPU[uOFM5OzZizszNNF74OWlUSU6JRWK=
NCI-H1299M1OzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYf3PJNEUUN3ME22MlY{OTdzIN88US=>M2XKTXNCVkeHUh?=
BT-549MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTZwNk[4PFkh|ryPMoTXV2FPT0WU
J-RT3-T3-5M3rFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHzTWM2OD14Lki2PUDPxE1?M{LV[HNCVkeHUh?=
SW756NIPJe|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTZwOUGxO|Yh|ryPNI\jTHpUSU6JRWK=
DJM-1NVrPe|lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX62Vmc1UUN3ME22MlkzODF{IN88US=>MY\TRW5ITVJ?
GP5dMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTZwOUezPVQh|ryPMnX0V2FPT0WU
MOLT-4NVXpV2NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmG2TWM2OD15LkCyNVM2KM7:TR?=MVjTRW5ITVJ?
NCI-H28MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzvTWM2OD15LkG2OFA2KM7:TR?=NUPZUYY{W0GQR1XS
MN-60NWLYeFJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXzeJU6UUN3ME23MlI5ODh7IN88US=>MXvTRW5ITVJ?
RMG-IMnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjKV5hkUUN3ME23MlM6Ojl4IN88US=>MlTLV2FPT0WU
COLO-800MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzKUXdEUUN3ME23MlQyPDR4IN88US=>MWXTRW5ITVJ?
DBMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTjRYhCUUN3ME23MlYyODB3IN88US=>MV7TRW5ITVJ?
Ca-SkiNVjTUWV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTdwNkSyOVkh|ryPNULZRXpDW0GQR1XS
HELNGXuOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFqydm9KSzVyPUeuO|EzODNizszNMXnTRW5ITVJ?
NH-12MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmG0TWM2OD15LkeyPFA5KM7:TR?=M1rKR3NCVkeHUh?=
LB373-MEL-DMoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTdwN{[3O|Eh|ryPMlXnV2FPT0WU
SW900NETDZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTdwOEKxNlEh|ryPM4TRTnNCVkeHUh?=
JVM-3MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjXTWM2OD15Lki5OVk6KM7:TR?=MnyyV2FPT0WU
OAW-28NGSyUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXiwPZc1UUN3ME23Mlk1PTd6IN88US=>NGPLUJhUSU6JRWK=
KURAMOCHINV;VXJhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXnfJlbUUN3ME23Mlk1QDFzIN88US=>M4LZPHNCVkeHUh?=
BE-13MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7JTWM2OD15Lkm4NVEzKM7:TR?=NFPNOphUSU6JRWK=
VMRC-RCZMn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXEOoJKSzVyPUiuNFE3QTdizszNMoXSV2FPT0WU
NCI-H727NXvUW3V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLsTWM2OD16LkGwOFIh|ryPNWXI[5U4W0GQR1XS
SW1710NIDHT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXqPY1KSzVyPUiuNVg2OTVizszNNV2xVZM1W0GQR1XS
D-502MGMnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXJRoVKSzVyPUiuNlkzQDJizszNMYHTRW5ITVJ?
NCI-H1993M{fKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTTVWNZUUN3ME24MlM{PjNzIN88US=>MWnTRW5ITVJ?
SCC-4NYfKVpZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HvSWlEPTB;OD60OFA2QSEQvF2=M4jpRXNCVkeHUh?=
HAL-01NILFPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEi4UIxKSzVyPUiuOVE6OSEQvF2=NV3VWnlRW0GQR1XS
GT3TKBNVzUOJV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PnZ2lEPTB;OD62O|k3PCEQvF2=MUPTRW5ITVJ?
SK-OV-3MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG[yfmhKSzVyPUiuO|E{OjlizszNNEPDWJZUSU6JRWK=
COLO-829MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRThwOEC5O|Yh|ryPM4XjPHNCVkeHUh?=
OCI-AML2NFvZZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfqdmdKSzVyPUiuPVU1QDFizszNMmi4V2FPT0WU
OS-RC-2NEfVTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2GwdGlEPTB;OT6wNlE6KM7:TR?=NEDVS21USU6JRWK=
BFTC-909MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;kfY5KSzVyPUmuNFY4QTlizszNNVjwNG5XW0GQR1XS
EW-11NVT5XI1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fSdWlEPTB;OT6xO|Y2OyEQvF2=NH;tSZVUSU6JRWK=
HCE-4MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvOTWM2OD17LkKxOVU5KM7:TR?=NFj4V4NUSU6JRWK=
BALL-1M1LTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfZblFOUUN3ME25MlIyQTB5IN88US=>NVz2bHUzW0GQR1XS
SF539MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTHW4xiUUN3ME25MlI{PTZ{IN88US=>MnfXV2FPT0WU
CAMA-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIm2OmxKSzVyPUmuNlgyOjhizszNMYfTRW5ITVJ?
C32M1\DSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTlwM{OwOlQh|ryPM2LCc3NCVkeHUh?=
NCI-H1703Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TsXGlEPTB;OT6zOFM4PSEQvF2=NVfpO5VEW0GQR1XS
NCI-H1650NULCXHdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTlwNkC5OFYh|ryPM{HOeXNCVkeHUh?=
NCI-H1563NHGyVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrUVZl7UUN3ME25Mlc3ODNzIN88US=>M2Wy[3NCVkeHUh?=
CAL-85-1MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vBSWlEPTB;OT64O|M5OyEQvF2=NIXDR5lUSU6JRWK=
UM-UC-3NFi5dFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;wTWM2OD17Lkm1NFMh|ryPMl74V2FPT0WU
BxPC-3MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTQTY9TUUN3ME2xNE4xQTd{IN88US=>MlP5V2FPT0WU
MHH-PREB-1MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13qVmlEPTB;MUCuNVk6QSEQvF2=M1:0cHNCVkeHUh?=
DELNVvkdGd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPMe2FKSzVyPUGwMlM6PDZizszNNIPtVI5USU6JRWK=
HuCCT1NHewPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTFyLk[wN|Mh|ryPM{PjcnNCVkeHUh?=
OVCAR-4NIS1WFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTpfIFKSzVyPUGwMlg5OzVizszNMlHNV2FPT0WU
CAL-72MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX65TXZsUUN3ME2xNE46OzlzIN88US=>MUPTRW5ITVJ?
HCC1954M2\EVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rXPWlEPTB;MUGuNFc2PCEQvF2=MVrTRW5ITVJ?
EFO-21MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DsV2lEPTB;MUGuNVA1PSEQvF2=MYTTRW5ITVJ?
FTC-133NV7rSmNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mkf4TWM2OD1zMT6xOFA4KM7:TR?=NX\kWlRvW0GQR1XS
SK-MEL-24MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTFzLkKzOlYh|ryPM17PPHNCVkeHUh?=
UACC-62MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1X1UGlEPTB;MUGuNlM3QCEQvF2=MWPTRW5ITVJ?
NCI-H650NGT6OJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XjNWlEPTB;MUGuNlQyQCEQvF2=NEHqTo5USU6JRWK=
ALL-POMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDBZYd4UUN3ME2xNU4zPTF{IN88US=>NH7uUIlUSU6JRWK=
T84NFHhd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTFzLkO5NFch|ryPNIrDUlBUSU6JRWK=
IST-MEL1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTFzLkS1OVkh|ryPNXPiRYV[W0GQR1XS
SW626NEn5bYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTFzLkW3OVUh|ryPNXvEXW1bW0GQR1XS
RPMI-2650MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfzboE{UUN3ME2xNU42QDh3IN88US=>MY\TRW5ITVJ?
MC-IXCMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrOO4VOUUN3ME2xNU43PzJ6IN88US=>Mn;SV2FPT0WU
HOP-62NFzWSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HoZWlEPTB;MUGuOlc3PCEQvF2=Ml\SV2FPT0WU
NOS-1Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PMSmlEPTB;MUGuO|ExQSEQvF2=NYiwdpBNW0GQR1XS
SW1573M3HiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXCTWM2OD1zMT63Nlk2KM7:TR?=Mni2V2FPT0WU
WM-115MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIriXY5KSzVyPUGxMlc2QDhizszNMlXBV2FPT0WU
HuO9NU\acnpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPPTWM2OD1zMT64O|c1KM7:TR?=MUfTRW5ITVJ?
YAPCNHXaWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTFzLkmyOVkh|ryPMW\TRW5ITVJ?
MDA-MB-453NETZZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTiTWM2OD1zMT65OVE2KM7:TR?=MlHYV2FPT0WU
NCI-H596M{K5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlL2TWM2OD1zMj6wN|Y6KM7:TR?=NV3BOpl2W0GQR1XS
A172NIDqe3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7h[lNKSzVyPUGyMlA4QThizszNNGqxd3dUSU6JRWK=
RS4-11MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXoWGpKSzVyPUGyMlE4OjVizszNNXvjOVV7W0GQR1XS
HCC1937NFTiW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TwNGlEPTB;MUKuO|U3PCEQvF2=MWLTRW5ITVJ?
SW837NUPjZVNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TUdGlEPTB;MUKuPVAzQCEQvF2=NXzsRm0yW0GQR1XS
NMC-G1M1LOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTF{LkmyN|Qh|ryPM1f1UHNCVkeHUh?=
PFSK-1M1vNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTF|LkC2JO69VQ>?NV3xRlNwW0GQR1XS
DBTRG-05MGNY\ySVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrL[3I6UUN3ME2xN{4xPjN{IN88US=>M3fUfXNCVkeHUh?=
SK-UT-1M3vjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7OU2RjUUN3ME2xN{4yODh|IN88US=>MUfTRW5ITVJ?
OVCAR-5M1T0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzCd29KSzVyPUGzMlE2QTNizszNM4HuZnNCVkeHUh?=
8505CMmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDNOlVPUUN3ME2xN{4zODZ5IN88US=>M4P3bXNCVkeHUh?=
SK-MEL-1MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfZTVJRUUN3ME2xN{44OTN3IN88US=>M3qxNHNCVkeHUh?=
LK-2NH;SbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XoW2lEPTB;MUOuO|Y{QSEQvF2=MnTuV2FPT0WU
OE33MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfMbZA2UUN3ME2xN{44QDZizszNNYTReWRKW0GQR1XS
Ramos-2G6-4C10M2LlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGe5bWxKSzVyPUG0MlAzODJizszNM{HmOnNCVkeHUh?=
EW-13M2rzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfyV4lKSzVyPUG0MlA{PTJizszNM{Cx[HNCVkeHUh?=
NCI-H1793NVvjVZVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3uyemlEPTB;MUSuNlA5PyEQvF2=M2iwVXNCVkeHUh?=
BHT-101MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTF2LkK0NUDPxE1?NFS5U2NUSU6JRWK=
RKOM2rOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLyTWM2OD1zND61NFc2KM7:TR?=MmDqV2FPT0WU
NEC8MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTF2LkW0O|Ih|ryPMlTYV2FPT0WU
PANC-10-05M2rtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfj[2l4UUN3ME2xOE43OjR5IN88US=>MXzTRW5ITVJ?
NCI-H2030MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTF2Lk[0OFgh|ryPNG\ke2tUSU6JRWK=
C2BBe1M2XQbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rx[mlEPTB;MUSuO|Y1KM7:TR?=NHzqVI1USU6JRWK=
EM-2NGC0N3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTF2Lki1O|Yh|ryPNESxRXdUSU6JRWK=
HCC1395MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTYdFExUUN3ME2xOE46OzN6IN88US=>MkL4V2FPT0WU
A2058NUnzfGRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLXTZB[UUN3ME2xOU4xPDB7IN88US=>M4W4bnNCVkeHUh?=
SW1463M1fP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTF3LkC0PFUh|ryPMnPRV2FPT0WU
J82NFPHV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTF3LkC1O{DPxE1?MX7TRW5ITVJ?
CAL-120NHHUUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYW5Z4Z[UUN3ME2xOU4yPDR5IN88US=>M3;CO3NCVkeHUh?=
COLO-824M{[1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLvTWM2OD1zNT6xOVc6KM7:TR?=MUnTRW5ITVJ?
LNCaP-Clone-FGCMlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELhOYdKSzVyPUG1MlQzPDhizszNMVLTRW5ITVJ?
CP66-MELMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\XTWM2OD1zNT60Olg5KM7:TR?=MX7TRW5ITVJ?
OC-314NHfuUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DDUWlEPTB;MUWuOFcyPCEQvF2=MUHTRW5ITVJ?
OVCAR-8NHr4b5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPJVlFKSzVyPUG1Mlg5PjFizszNNGrC[HdUSU6JRWK=
MFE-280M4PS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTBUYZRUUN3ME2xOk4xPDh6IN88US=>NHHaXYJUSU6JRWK=
MHH-NB-11MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLLTWM2OD1zNj6wPFM6KM7:TR?=M4XTPHNCVkeHUh?=
SW1990M3;vS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7BTWM2OD1zNj6xO|U2KM7:TR?=MULTRW5ITVJ?
U-266MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTF4LkKyPVkh|ryPM{LTVnNCVkeHUh?=
MFM-223MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDBe3hKSzVyPUG2MlM6PjVizszNNFvIVGNUSU6JRWK=
L-363NEfqbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jq[WlEPTB;MU[uOFU4PyEQvF2=MlnaV2FPT0WU
MCF7NWrGOJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPrTWM2OD1zNj60O|I{KM7:TR?=M2PBSXNCVkeHUh?=
SK-MEL-3MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7CZYFSUUN3ME2xOk41Pzh5IN88US=>NVrPSVF7W0GQR1XS
HHNGfkVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofSTWM2OD1zNj61NVYzKM7:TR?=NVLxendtW0GQR1XS
no-10MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPtVllKSzVyPUG2MlY{PDNizszNM{LjWnNCVkeHUh?=
HuP-T3MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTF4Lk[1O|Yh|ryPNVvaPYVUW0GQR1XS
QIMR-WILM2TUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXJbYx{UUN3ME2xOk44OTB3IN88US=>MYjTRW5ITVJ?
NCI-H1092M1TNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nzXGlEPTB;MU[uPFMyPiEQvF2=NUDmVlRsW0GQR1XS
MZ2-MELM4jZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTF4Lki0NFMh|ryPMYHTRW5ITVJ?
ES3MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjSTWM2OD1zNj65NVM1KM7:TR?=NEjaPVlUSU6JRWK=
COLO-684MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkn5TWM2OD1zNj65OFc4KM7:TR?=M2fuSnNCVkeHUh?=
NCI-H661M3rnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTF4Lkm2PVQh|ryPNXrnbYo1W0GQR1XS
CP50-MEL-BMlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTF5LkCzOFMh|ryPM2PnOXNCVkeHUh?=
NCI-H2405MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33VN2lEPTB;MUeuNVk4PCEQvF2=NGCzOoJUSU6JRWK=
U-2-OSMln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rNXGlEPTB;MUeuOVMxPyEQvF2=M4\IPHNCVkeHUh?=
RERF-LC-MSNX7yVpdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfCTWM2OD1zNz61OVA5KM7:TR?=NEnQWHRUSU6JRWK=
NCI-H2342MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vVXWlEPTB;MUeuOVU4KM7:TR?=Ml7HV2FPT0WU
ES8MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTs[3NCUUN3ME2xO{43ODh5IN88US=>Mn;KV2FPT0WU
MOLT-16M3WzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTF5Lki5N|Qh|ryPM2XXO3NCVkeHUh?=
RH-18Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTF6LkCwN|Uh|ryPMVjTRW5ITVJ?
D-283MEDM2XxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vMcmlEPTB;MUiuNFA5QCEQvF2=M{\qd3NCVkeHUh?=
RCC10RGBNV25SVd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTF6LkC1OVkh|ryPM{XzN3NCVkeHUh?=
NCI-H1437NGnFUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTuTZNtUUN3ME2xPE4yPjRzIN88US=>MnTNV2FPT0WU
SW982MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nKO2lEPTB;MUiuNlY4OSEQvF2=MW\TRW5ITVJ?
IST-MES1Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXXWpJKSzVyPUG4MlQ1OjhizszNMYfTRW5ITVJ?
A704M37wTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTF6LkS3OVMh|ryPNVHVXIFwW0GQR1XS
ESS-1MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTPOGJKSzVyPUG4MlUzODVizszNMVPTRW5ITVJ?
SCHNInvZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTTbXp3UUN3ME2xPE43PDV4IN88US=>MnTCV2FPT0WU
COLO-320-HSRNVvpWHQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jIRmlEPTB;MUiuO|Q3KM7:TR?=NXXERpl5W0GQR1XS
Mo-TNXTVO2pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnjTWM2OD1zOD64NlA1KM7:TR?=M1TwOnNCVkeHUh?=
Saos-2MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;iSHFKSzVyPUG5MlEyPjJizszNNEiyTVhUSU6JRWK=
SW684NV[3b|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3CTWM2OD1zOT6xN|I3KM7:TR?=M1nhdnNCVkeHUh?=
KMOE-2NFXtXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHryeFRKSzVyPUG5MlIzPDJizszNMVXTRW5ITVJ?
MMAC-SFMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTF7LkK2NFch|ryPNXXp[Fl4W0GQR1XS
JARM4Xi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrKTWM2OD1zOT6yPVkh|ryPMUPTRW5ITVJ?
SK-MEL-28NUfMXFI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3K1SmlEPTB;MUmuN|M3OyEQvF2=MXTTRW5ITVJ?
KNS-81-FDNXS5fXpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPPS2VHUUN3ME2xPU42PDZ6IN88US=>NEfxbXpUSU6JRWK=
ES7MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3ze2lKSzVyPUG5MlYzQTJizszNMl:0V2FPT0WU
AsPC-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzHfGNKSzVyPUG5MlY1PzFizszNNFHHVpBUSU6JRWK=
NCI-H1155M{e1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXiRnU4UUN3ME2xPU44OjN6IN88US=>NVvXOYVWW0GQR1XS
KYSE-510NHLvcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHsbIJKSzVyPUG5Mlg4PDhizszNMV\TRW5ITVJ?
ES1NYTzOplmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDrcmZKSzVyPUG5MlkzOTNizszNMoq3V2FPT0WU
PC-3M4jJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;hWFNKSzVyPUG5Mlk3ODRizszNNIn4OY1USU6JRWK=
GCTNFHHR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XycGlEPTB;MkCuN|AzPiEQvF2=M3LZU3NCVkeHUh?=
KARPAS-299M1H0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\OfXRKSzVyPUKwMlM1OjJizszNMnSwV2FPT0WU
DOHH-2NYXRNlVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LmPGlEPTB;MkCuOVQ3OyEQvF2=MXPTRW5ITVJ?
COLO-741MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rDZWlEPTB;MkCuOlYh|ryPM{nLT3NCVkeHUh?=
NCI-H1395NFnkVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnlWZB{UUN3ME2yNE43Pjl5IN88US=>MVXTRW5ITVJ?
HCC1187NY\wO4V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;BTZU1UUN3ME2yNE43PzN2IN88US=>MXPTRW5ITVJ?
BeckerMmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHq3[IdKSzVyPUKwMlczODFizszNNUi5OHpkW0GQR1XS
LU-134-ANFOxOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17CbWlEPTB;MkGuNVAzPiEQvF2=NYHYNGk{W0GQR1XS
MKN45NY\LXoJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XqeGlEPTB;MkGuNVU2OSEQvF2=M1POXnNCVkeHUh?=
LC-2-adNYH1[3dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnroTWM2OD1{MT6yO|I6KM7:TR?=NE\FRnJUSU6JRWK=
EW-24Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljlTWM2OD1{MT6zPVQ2KM7:TR?=M4P2c3NCVkeHUh?=
SK-N-ASM33aW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX25bZJpUUN3ME2yNU45Ojd4IN88US=>M4XWTXNCVkeHUh?=
NCI-H2052NGWxSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1ezPGlEPTB;MkGuPFk3OyEQvF2=NFzMVFBUSU6JRWK=
A4-FukMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEW3ZXhKSzVyPUKyMlE1OTlizszNM2LvZnNCVkeHUh?=
NB10M3nw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF35VmxKSzVyPUKyMlI{PzFizszNMWHTRW5ITVJ?
CHP-212MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTJ{LkOyNlIh|ryPNFK4O4tUSU6JRWK=
KM12NYPOSWg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfMNFlKSzVyPUKyMlM2PiEQvF2=NVfsb|V7W0GQR1XS
JEG-3MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHB[HZYUUN3ME2yNk4{PzhizszNM2TuTHNCVkeHUh?=
LN-405MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXYT5d[UUN3ME2yNk42QTF|IN88US=>MWDTRW5ITVJ?
HCT-15MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\6TWM2OD1{Mj63OFQyKM7:TR?=MmP0V2FPT0WU
MLMANGq0eFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{ixXGlEPTB;MkKuO|Q4KM7:TR?=NHfrNWlUSU6JRWK=
GI-1NUTqfZpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXzTWM2OD1{Mj63OlU5KM7:TR?=NWPTRVFvW0GQR1XS
RT-112NYHrc2F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTJ{Lki2NVYh|ryPM{HCfXNCVkeHUh?=
MPP-89NHXIZ|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\mTWM2OD1{Mj64OlYyKM7:TR?=NWfPe4RIW0GQR1XS
A3-KAWNHXk[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;6TWM2OD1{Mz6xNFA{KM7:TR?=M3O5[HNCVkeHUh?=
KALS-1NFj0ZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\WNI1PUUN3ME2yN{4yPDF2IN88US=>NYj5NIRrW0GQR1XS
SF126NYThRWM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHUTWM2OD1{Mz62PVI1KM7:TR?=M2[xUnNCVkeHUh?=
SiHaNUnxemtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTJ|LkmzNlch|ryPNF7CTo9USU6JRWK=
MDA-MB-415M1f5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\6bo1KSzVyPUKzMlk1QTlizszNMl3YV2FPT0WU
DaoyMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTJ2LkGyOkDPxE1?NFPId29USU6JRWK=
COR-L23M3jie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfPVppqUUN3ME2yOE4yPzZ5IN88US=>M3fvXHNCVkeHUh?=
KG-1NWC4[IVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fXVGlEPTB;MkSuNVkzQCEQvF2=M2\6cnNCVkeHUh?=
L-428MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGj3fo9KSzVyPUK0MlU4QTFizszNMnLNV2FPT0WU
NCI-H520M4\RWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4W3WGlEPTB;MkSuPFg3OSEQvF2=NELO[G9USU6JRWK=
COLO-792M4LXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfnWJZVUUN3ME2yOU4zPzN{IN88US=>NXy3W|VsW0GQR1XS
NB12MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrJcnFKSzVyPUK1MlI6PDdizszNMnnwV2FPT0WU
GAKNEDX[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rKUmlEPTB;MkWuNlk3OyEQvF2=NX;SZYZpW0GQR1XS
SW780NXezVZV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITle3FKSzVyPUK1MlMzPjRizszNM4nzSXNCVkeHUh?=
GB-1NIPxTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfnOFFKSzVyPUK1MlQxPjlizszNNFXkNldUSU6JRWK=
P12-ICHIKAWAMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\Yc4RKSzVyPUK1MlQ4QDVizszNNELxRVhUSU6JRWK=
NCI-H1651MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTMTWM2OD1{NT61PVch|ryPMWPTRW5ITVJ?
KE-37NUDF[XFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWn5ZVRXUUN3ME2yOU44OzF3IN88US=>MXnTRW5ITVJ?
CCRF-CEMNYrpXJFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmS3TWM2OD1{NT65Olch|ryPNWjM[VlqW0GQR1XS
SF295MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTJ4LkC0NlUh|ryPNVjCWo1KW0GQR1XS
G-361Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnWyTWM2OD1{Nj6xNFI4KM7:TR?=NFm4T4NUSU6JRWK=
HOP-92M33IVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TTWmlEPTB;Mk[uNVIzPiEQvF2=MXXTRW5ITVJ?
UMC-11M1PmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTJ4LkS1NVQh|ryPNH;S[FVUSU6JRWK=
IST-SL1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITw[GhKSzVyPUK2MlY2QTFizszNNFXESZFUSU6JRWK=
TE-11NGnHWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTJ4Lke3OVIh|ryPMoTHV2FPT0WU
NCI-H1304NYLIfJQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TPRWlEPTB;Mk[uPVExQCEQvF2=MoTyV2FPT0WU
SJSA-1NFTSXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLkem9KSzVyPUK3MlAyPzZizszNMVfTRW5ITVJ?
BCPAPNGjXSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\YV2lEPTB;MkeuNVM4KM7:TR?=MnvVV2FPT0WU
HTC-C3MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVy4OHlzUUN3ME2yO{4zPTZzIN88US=>MmPQV2FPT0WU
EW-16M2PZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTJ5LkK5OFch|ryPNF\PNFZUSU6JRWK=
HT-144NYnzZ4NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTJ5LkSwN|Ih|ryPM3\4U3NCVkeHUh?=
MHH-ES-1NVKwPGJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTJ5LkS0OFch|ryPNInpSFJUSU6JRWK=
T98GNIP6T5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rkfWlEPTB;MkeuOVg1PiEQvF2=M17mZXNCVkeHUh?=
RPMI-8866NEC2XJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moi0TWM2OD1{Nz63OVYzKM7:TR?=MU\TRW5ITVJ?
BENMlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTJ5Lki1NVch|ryPMkHhV2FPT0WU
MDA-MB-231NXHxSFJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\3TWM2OD1{OD6yO|k2KM7:TR?=MlT4V2FPT0WU
HuH-7NGnBT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTJ6LkSwNlgh|ryPNFj4PWNUSU6JRWK=
SK-N-FINGjBPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjsTWM2OD1{OD60N|Mh|ryPMV7TRW5ITVJ?
AN3-CANW\PXm9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LtfmlEPTB;MkiuOFM6PSEQvF2=MXnTRW5ITVJ?
EGI-1M3n2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDXOFRKSzVyPUK4MlU6OjhizszNNVn2VlV2W0GQR1XS
697MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfTTWM2OD1{OD62N|MyKM7:TR?=M1LB[nNCVkeHUh?=
TCCSUPNYjlR3lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfncWZEUUN3ME2yPE43PDF6IN88US=>NYDLeWdWW0GQR1XS
GR-STM{nLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TBdWlEPTB;MkiuOlY6PiEQvF2=M33JW3NCVkeHUh?=
SK-N-DZM3LYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTJ6Lk[4PFUh|ryPNWjzb5NNW0GQR1XS
MIA-PaCa-2MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPzWmd5UUN3ME2yPE44QTV7IN88US=>NH;Ve41USU6JRWK=
IGR-1NWjteJVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETScmxKSzVyPUK4Mlg5PzRizszNMmf3V2FPT0WU
BFTC-905NULNUGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTJ7LkK3NFUh|ryPM3q4fHNCVkeHUh?=
NCI-H1581NUK0eVJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTJ7LkOxOFUh|ryPMWPTRW5ITVJ?
RDNWHYZ4l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Sx[WlEPTB;MkmuOVI{OyEQvF2=NGLiW2pUSU6JRWK=
SF268NGnWV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7TXnZ[UUN3ME2yPU42QTNzIN88US=>MVzTRW5ITVJ?
SHP-77MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\SVJNGUUN3ME2yPU43OTh{IN88US=>NFX2NXZUSU6JRWK=
D-566MGMn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTJ7LkmzPVMh|ryPM3jienNCVkeHUh?=
TGBC1TKBMkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjLTWM2OD1|MD6xNlM5KM7:TR?=NWmyWHJSW0GQR1XS
MEL-HONXLENI5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1ftSGlEPTB;M{CuNVQzOyEQvF2=NEXpW5NUSU6JRWK=
SJRH30MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFK0UG5KSzVyPUOwMlIyODhizszNM1jkVnNCVkeHUh?=
D-336MGM1Prdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfTTWM2OD1|MD6yPFkzKM7:TR?=NF:3b3pUSU6JRWK=
C3AMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzoPYtKSzVyPUOwMlI6OjdizszNNH\WZotUSU6JRWK=
Calu-6NI\uXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrJU45KSzVyPUOwMlI6PjNizszNNIfkZVFUSU6JRWK=
MZ1-PCM3PFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTNyLkO5N{DPxE1?MVzTRW5ITVJ?
KYSE-70NUT1SY5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTBNXpKSzVyPUOwMlUyOTRizszNNIfUc5RUSU6JRWK=
CAPAN-1NGLuUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXm5XIFxUUN3ME2zNE42OThzIN88US=>MVHTRW5ITVJ?
DK-MGNEPCSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fSd2lEPTB;M{CuOVQ2PiEQvF2=NVjqeGJ3W0GQR1XS
SK-HEP-1MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTNyLk[zNlYh|ryPMWXTRW5ITVJ?
MS-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3f1fGlEPTB;M{CuPFg5QSEQvF2=NIXpNnVUSU6JRWK=
GI-ME-NNVjHZ5lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Hpe2lEPTB;M{GuNFU4OSEQvF2=Mnj4V2FPT0WU
NCI-H510AMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTNzLkSwNFYh|ryPNEHUO5JUSU6JRWK=
NB17MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTNzLkWxPFUh|ryPM2fwTnNCVkeHUh?=
639-VNVPpOYpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFr6VmRKSzVyPUOxMlUzPDNizszNMnnoV2FPT0WU
CAL-51NFuwU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXaSI5zUUN3ME2zNU42PjZ5IN88US=>Mlq1V2FPT0WU
HGC-27MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPuU3NKSzVyPUOxMlU5PzNizszNNWHudVV6W0GQR1XS
GOTOM3XiOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjz[YF6UUN3ME2zNU45PTB4IN88US=>M4LrNXNCVkeHUh?=
ChaGo-K-1MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLGTWM2OD1|Mj6wNFch|ryPM3PRdnNCVkeHUh?=
RO82-W-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTN{LkG2NFQh|ryPMXPTRW5ITVJ?
SH-4MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDmXZRKSzVyPUOyMlE5PThizszNM2jWXXNCVkeHUh?=
A204NIPI[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGT4NFVKSzVyPUOyMlUxPjlizszNNGrrU3pUSU6JRWK=
DMS-273Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlmzTWM2OD1|Mj61N|IzKM7:TR?=NFz1N2dUSU6JRWK=
KGNNFnEeVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjSUIhpUUN3ME2zNk43OzNizszNNXHtToRQW0GQR1XS
SK-MEL-2NEL2VVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfOd5hKSzVyPUOyMlY2OjdizszNM{nIfXNCVkeHUh?=
NCI-H2228MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjwV3lKSzVyPUOyMlY3ODJizszNMm\kV2FPT0WU
MKN28NEG4PFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HxSGlEPTB;M{KuO|g{QCEQvF2=NWK0TVVjW0GQR1XS
H-EMC-SSM13TOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\QTWM2OD1|Mj65Olc5KM7:TR?=MlHNV2FPT0WU
ATN-1Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nEVmlEPTB;M{OuNVQyPiEQvF2=M{\IcHNCVkeHUh?=
D-263MGNUThZWp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzzTWM2OD1|Mz64N|c5KM7:TR?=M17jVXNCVkeHUh?=
LU-135MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXRXFZKSzVyPUOzMlg5OjlizszNNF\Wc45USU6JRWK=
C8166NYq1OmliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTN|Lki4OVQh|ryPMWPTRW5ITVJ?
T-24NYfkUJhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7Ecm5KSzVyPUO0MlAzODVizszNMYLTRW5ITVJ?
MewoM{C2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnruTWM2OD1|ND6xN|Q6KM7:TR?=NWHz[ZpGW0GQR1XS
22RV1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITXdJJKSzVyPUO0MlE4PTRizszNNYHsXWhuW0GQR1XS
KM-H2MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4D5RmlEPTB;M{SuNVc4QSEQvF2=Mn;RV2FPT0WU
NCI-H2122M3LkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;je4J4UUN3ME2zOE4{PDdzIN88US=>MoW1V2FPT0WU
ABC-1M1fq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfs[Y42UUN3ME2zOE4{Pjl|IN88US=>MVTTRW5ITVJ?
NCI-H1355NILIOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDlXYdKSzVyPUO0MlM5QDlizszNMlXNV2FPT0WU
NOMO-1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPmfI9wUUN3ME2zOE42PzB|IN88US=>MULTRW5ITVJ?
MZ7-melMl\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTYTWM2OD1|ND62OFg4KM7:TR?=MX;TRW5ITVJ?
NCI-H810MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTN2LkeyO|gh|ryPNITIU|JUSU6JRWK=
D-392MGMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTweVZKSzVyPUO1MlA2PjVizszNNFjUNlZUSU6JRWK=
LB771-HNCMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUT1N4o4UUN3ME2zOU4yPjV6IN88US=>M{nQXnNCVkeHUh?=
COLO-679MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3:1cWlEPTB;M{WuN|g5KM7:TR?=NEHpTnRUSU6JRWK=
SK-PN-DWM4LTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3kTWM2OD1|NT60N|Y6KM7:TR?=M4\hSHNCVkeHUh?=
VA-ES-BJMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTN3LkS2OFkh|ryPMVjTRW5ITVJ?
KNS-42MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYW2XGg5UUN3ME2zOU42QDJ4IN88US=>NIf5TJVUSU6JRWK=
RVH-421NYXRSYZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;KWGlEPTB;M{WuO|Y1PSEQvF2=Mn3FV2FPT0WU
P30-OHKMlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTN3Lki3OVIh|ryPMnOyV2FPT0WU
G-402M1POU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnBUJFKSzVyPUO1Mlk5PjdizszNMoDFV2FPT0WU
S-117NFLTdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnKTWM2OD1|Nj6zNFA5KM7:TR?=Mn3WV2FPT0WU
RXF393M4LzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTN4LkO3PFUh|ryPNWK5N2d[W0GQR1XS
LCLC-103HNGf0cFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TnW2lEPTB;M{[uO|gxOyEQvF2=MYfTRW5ITVJ?
U-118-MGNWrIfXpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULDOGd4UUN3ME2zOk45QDR5IN88US=>MX3TRW5ITVJ?
8-MG-BAMn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfs[YRKSzVyPUO2Mlk1QDNizszNMnvOV2FPT0WU
MFH-inoM{jENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTN5LkOzO|Eh|ryPNETTNmtUSU6JRWK=
NCI-H23MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoroTWM2OD1|Nz60NVk3KM7:TR?=M{fzenNCVkeHUh?=
NCI-H446MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHKTWM2OD1|Nz60PFYzKM7:TR?=NIjVbYpUSU6JRWK=
LU-99ANX3yb2FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;jZ283UUN3ME2zO{42PzNzIN88US=>Mlv2V2FPT0WU
KP-N-YNNUjabXdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHuWlRxUUN3ME2zO{43OTl3IN88US=>MlLLV2FPT0WU
SCC-9MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;lZlhTUUN3ME2zO{44QDN6IN88US=>MkGyV2FPT0WU
EFM-19NFzsdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIr2cXpKSzVyPUO3Mlc6PjdizszNMnHNV2FPT0WU
A427NFv6TpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTN5LkmxNFch|ryPMX\TRW5ITVJ?
LB831-BLCM2HrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTN6Lk[wN|kh|ryPNYjWdYVIW0GQR1XS
HOSNIXFUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moi3TWM2OD1|OT62Nlc{KM7:TR?=NIr6UZhUSU6JRWK=
LAN-6MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDM[lB[UUN3ME20NE4xOTF{IN88US=>M3fBdHNCVkeHUh?=
U251NFLFW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vQUWlEPTB;NECuOFA2PCEQvF2=MnnaV2FPT0WU
SNU-387MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTRyLkS1OVMh|ryPM1zlfXNCVkeHUh?=
DMS-79NUSwSIwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDqZnRKSzVyPUSwMlU5QDlizszNNFLnfnNUSU6JRWK=
SK-LU-1MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLGTWM2OD12MD62OVY5KM7:TR?=M32xeXNCVkeHUh?=
HTMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXuWJNKSzVyPUSwMlY3OzlizszNNEjlSY9USU6JRWK=
KP-N-YSM1iyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULDNlhEUUN3ME20NE43PzZ6IN88US=>NVfkNWxmW0GQR1XS
DMS-114M13YWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILTZVNKSzVyPUSwMlg{PzRizszNNW[zW|ZUW0GQR1XS
HUTU-80MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTRzLkC1Olkh|ryPMXnTRW5ITVJ?
ONS-76NEPMTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7FTI44UUN3ME20NU41PzB7IN88US=>MnzWV2FPT0WU
A673Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rYbWlEPTB;NEGuOVE2PyEQvF2=NVrYbooxW0GQR1XS
HPAF-IIMmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkj3TWM2OD12MT62O|A6KM7:TR?=NY\DSZB4W0GQR1XS
UACC-257NVPib4pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkW1TWM2OD12MT63N|Y6KM7:TR?=M4PxfXNCVkeHUh?=
EW-22M2HBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrVTWM2OD12MT64Olk4KM7:TR?=NUDhUWl2W0GQR1XS
NCI-H1755MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTRzLki3NlUh|ryPNYDnTYtRW0GQR1XS
KYSE-150MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{X2[WlEPTB;NEKuNVc5OiEQvF2=NVL3fFBiW0GQR1XS
CGTH-W-1MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTR{LkS5OVUh|ryPNIfkVmNUSU6JRWK=
NB13MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLIfG5EUUN3ME20Nk43OjF5IN88US=>NWPN[XlLW0GQR1XS
SW872NFvoflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHEfoFKSzVyPUSyMlY{OzFizszNNVHKfnZZW0GQR1XS
KP-4NF7ZSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPsUHZKSzVyPUSyMlg5OzJizszNM{fOZnNCVkeHUh?=
HCC38NFPXOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzuTWM2OD12Mj65OlE5KM7:TR?=M{LJd3NCVkeHUh?=
BB49-HNCM{DhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTR|LkKzOVYh|ryPM2j1enNCVkeHUh?=
CAL-62Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTR|LkSwNlgh|ryPMoTtV2FPT0WU
NCI-H2029NHy4UGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXESVVKSzVyPUSzMlU2QDFizszNMVnTRW5ITVJ?
M14NXixdos2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M163UWlEPTB;NESuNVM{OiEQvF2=MWjTRW5ITVJ?
COLO-680NM3XORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7iTWM2OD12ND6zN|kh|ryPMWLTRW5ITVJ?
Hs-578-TNX7IcYdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTR3LkCyPVQh|ryPMXjTRW5ITVJ?
MSTO-211HM2Tvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTR3Lkm0PFIh|ryPNWDQemd[W0GQR1XS
EW-1NYm5eYRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTR3Lkm2PFkh|ryPNYrRcnd6W0GQR1XS
SW948MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjBNFl6UUN3ME20Ok41PDZ{IN88US=>NEfJ[W9USU6JRWK=
NCI-H460NUTqNnc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mln3TWM2OD12Nj61NlMh|ryPNXLxfpNUW0GQR1XS
CAS-1MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPZfIJlUUN3ME20Ok44PzBzIN88US=>M1jJdnNCVkeHUh?=
TGBC11TKBM2PjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTR5LkG3O|ch|ryPM{HhNHNCVkeHUh?=
HD-MY-ZNIjYRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rOZWlEPTB;NEiuO|g3KM7:TR?=MmXPV2FPT0WU
NCI-H226NEPSSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DwbGlEPTB;NEmuO|c5PSEQvF2=M1fGNHNCVkeHUh?=
PA-1MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXy5eYF{UUN3ME20PU45OzN3IN88US=>MnKyV2FPT0WU
LB2518-MELNUjBRmhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnhVVdKSzVyPUS5Mlg4OjNizszNNF7BTVJUSU6JRWK=
A101DNYTzXJp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LOSGlEPTB;NEmuPVQzPSEQvF2=NIPs[2RUSU6JRWK=
NCI-H2087NULGfFJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTR7Lkm2PFIh|ryPNEjDSGdUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro kinase activity assays The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.

Cell Assay:

[1]

Cell lines NSCLC cells
Concentrations 0-10 μM
Incubation Time 1 hour
Method

1 × 104 NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 104 cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm.

Animal Study:

[1]

Animal Models Athymic NMRI-nu/nu female mice
Formulation In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80)
Dosages 20 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Li D, et al. Oncogene, 2008, 27(34), 4702-4711.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02501603 Recruiting Gastric Cancer|Gastroesophageal Junction Cancer Yonsei University July 2016 Phase 2
NCT02795156 Not yet recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boe  ...more SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer July 2016 Phase 2
NCT02780687 Recruiting Urologic Neoplasms Boehringer Ingelheim June 2016 Phase 2
NCT02183883 Not yet recruiting Non-small Cell Lung Cancer University College, London|Boehringer Ingelheim May 2016 Phase 2
NCT02716311 Not yet recruiting Non Small Cell Lung Cancer Intergroupe Francophone de Cancerologie Thoracique April 2016 Phase 2

view more

Chemical Information

Download Afatinib (BIBW2992) SDF
Molecular Weight (MW) 485.94
Formula

C24H25ClFN5O3

CAS No. 439081-18-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 97 mg/mL (199.61 mM)
Ethanol 15 mg/mL (30.86 mM)
Water <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose+0.2% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

Frequently Asked Questions

  • Question 1
    What’s the recommendation about reconstitution of the compound for in vivo animal study?

    Answer: For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Afatinib (BIBW2992) | Afatinib (BIBW2992) ic50 | Afatinib (BIBW2992) price | Afatinib (BIBW2992) cost | Afatinib (BIBW2992) solubility dmso | Afatinib (BIBW2992) purchase | Afatinib (BIBW2992) manufacturer | Afatinib (BIBW2992) research buy | Afatinib (BIBW2992) order | Afatinib (BIBW2992) mouse | Afatinib (BIBW2992) chemical structure | Afatinib (BIBW2992) mw | Afatinib (BIBW2992) molecular weight | Afatinib (BIBW2992) datasheet | Afatinib (BIBW2992) supplier | Afatinib (BIBW2992) in vitro | Afatinib (BIBW2992) cell line | Afatinib (BIBW2992) concentration | Afatinib (BIBW2992) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us